Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Abstract: The present disclosure is directed to methods of using a capsid assembly inhibitor for the treatment of hepatitis B virus infection.

Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.

Abstract: Tridentate cyclometalated complexes with rigid six-membered coordination rings of General Formula I having tunable emission wavelengths in the visible range. These emitters are suitable for full color displays and lighting applications.

Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.

Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: Non-water soluble cannabinoid acids are isolated from trichomes and flower of Cannabis genus by leaching with alkaline water. The leaching with alkaline water converts the cannabinoid acids to water soluble salts. The resulting solution of cannabinoid salts may be used as a source of acidic cannabinoids for pharmaceutical applications or the cannabinoid acid salts may be converted back to their acid form and precipitated into a high purity microcrystalline powder by acidification of the aqueous solution. Compounds that are not water soluble and do not form salts in alkaline water such as many pesticides, fungicides and off flavors will not be concentrated.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: A compound of formula (I) is provided. In the compound of formula (I), Q represents a group represented by formula Q1 or the like and the rest of the variable definitions are as set forth in the specification. The compounds of formula (I) have excellent control efficacy against harmful arthropods.

Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.

Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: A curing agent or a curing accelerator which is easy to synthesize and may cure an epoxy resin and the like, or may accelerate the curing is provided. A curing agent or a curing accelerator according to some embodiments of the present invention has a highly-coordinated silicon structure.

Abstract: A metadielectric composite oligomeric organic material according to the formula: wherein C is a linear chain oligomeric polarizable core with a system of conjugated multiple and single bonds wherein the linear chain oligomeric polarizable core possesses at least two different monomers with differing electron affinity, and the different monomers are positioned within the linear chain oligomeric polarizable core such that an electron affinity gradient is present, and the differing monomers have a low HOMO-LUMO bandgap between them, and there is at least one electron-donor group, D, attached to the linear chain oligomeric polarizable core, there is at least one electron-acceptor group, A, is attached to the linear chain oligomeric polarizable core, p? and q? represent the number of electron-donor and electron-acceptor groups present, respectively, and are any integer greater than zero, and at least one resistive insulating group is covalently attached to the molecular structure at any location.

Abstract: Disclosed is a process for the extraction of furfural. The process includes subjecting a composition comprising furfural, water, at least one acid and an aromatic solvent, with a boiling point higher than that of furfural, to a first separation step in a first liquid-liquid separator providing a first organic phase and a first aqueous phase; conveying the first organic phase along a first line to a distillation column and subjecting the first organic phase to a distillation step providing a top stream comprising furfural and a bottom stream comprising the aromatic solvent; subjecting the first aqueous phase and a portion of the bottom stream to a second separation step providing a second organic phase; conveying the second organic phase along a second line which either feeds its contents into the first line or into the distillation column and subjecting the resultant mixture to said distillation step.